All Stories

  1. Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19
  2. Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F–F′ Loop Perturbations
  3. Predictors associated with bleeding and thromboembolic complications in patients taking rivaroxaban-- a Singapore study
  4. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19
  5. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes
  6. Risk assessment of cultured meat
  7. Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement
  8. Role of Cytochrome P450 2C8 in Drug–Drug Interaction between Amiodarone and Nirmatrelvir/Ritonavir Via Physiologically‐Based Pharmacokinetic Modeling
  9. Development and verification of a physiologically‐based pharmacokinetic model of dronedarone and its active metabolite N‐desbutyldronedarone: application to prospective simulation of complex drug‐drug interaction with rivaroxaban.
  10. Lactobacillus paracasei IMC 502 ameliorate type 2 diabetes by mediating gut microbiota‐SCFAs ‐hormone/inflammation pathway in mice
  11. Identification of Optimal Urinary Biomarkers of Synthetic Cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZO-POXIZID, and BZO-CHMOXIZID for Illicit Abuse Monitoring
  12. Inhibition of cytochrome P450 2J2-mediated metabolism of rivaroxaban and arachidonic acid by ibrutinib and osimertinib
  13. Physiologically Based Pharmacokinetic Modelling‐Guided Dose Management of Oral Anticoagulants when Initiating Paxlovid for COVID ‐19 Treatment
  14. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
  15. Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore
  16. Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of Cytochrome P450 3A
  17. Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance
  18. Rational deuteration of dronedarone attenuates its toxicity in human hepatic HepG2 cells
  19. Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts
  20. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminate in Mechanism-Based Inactivation of Cytochrome P450 3A
  21. Antidiabetic effects of multi-species probiotic and its fermented milk in mice via restoring gut microbiota and intestinal barrier
  22. Febuxostat and its Major Acyl Glucuronide Metabolite are Potent Inhibitors of Organic Anion Transporter 3: Implications for Drug‐Drug Interactions with Rivaroxaban
  23. Transesterification of Indazole-3-Carboxamide Synthetic Cannabinoids: Identification of Metabolite Biomarker for Diagnosing Co-Abuse of 5F-MDMB-PINACA and Alcohol
  24. Inhibition of cytochrome P450 enzymes and uridine 5′-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions
  25. Application of a PBPK Model of Rivaroxaban to Prospective Simulations of Drug‐Drug‐Disease Interactions with Protein Kinase Inhibitors in CA‐VTE
  26. Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population
  27. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors
  28. Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse
  29. Preliminary discovery of novel markers for human cell line activation test (h-CLAT)
  30. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4
  31. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5
  32. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib
  33. Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents
  34. Fructose intolerance is not associated with malabsorption in patients with functional gastrointestinal disorders
  35. Mechanism-based Inactivation of Cytochrome P450 3A4 by Benzbromarone
  36. An exploratory analysis of effects of poyendarone, a deuterated analogue of dronedarone, on the canine model of paroxysmal atrial fibrillation
  37. Diagnosing intake and rationalizing toxicities associated with 5F-MDMB-PINACA and 4F-MDMB-BINACA abuse
  38. A compromised developmental trajectory of the infant gut microbiome and metabolome in atopic eczema
  39. Tryptophan–kynurenine ratio as a biomarker of bladder cancer
  40. Combination Bacillus Calmette-Guérin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer
  41. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen
  42. Increased Protein S-Glutathionylation in Leber’s Hereditary Optic Neuropathy (LHON)
  43. How the Deuteration of Dronedarone Can Modify Its Cardiovascular Profile: In Vivo Characterization of Electropharmacological Effects of Poyendarone, a Deuterated Analogue of Dronedarone
  44. Predicting human tissue exposures to xenobiotics using a bottom-up physiologically-based biokinetic model
  45. Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition
  46. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban
  47. Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing
  48. Faculty cooperation in teaching academic literacy using popular science texts: A case study
  49. Dose-Dependent Increase in Unconjugated Cinnamic Acid Concentration in Plasma Following Acute Consumption of Polyphenol Rich Curry in the Polyspice Study
  50. Reactive Metabolite-induced Protein Glutathionylation: A Potentially Novel Mechanism Underlying Acetaminophen Hepatotoxicity
  51. Rivaroxaban With and Without Amiodarone in Renal Impairment
  52. Recent advances in the applications of metabolomics in eye research
  53. Dronedarone-Induced Cardiac Mitochondrial Dysfunction & Its Mitigation by Epoxyeicosatrienoic Acids
  54. Polyphenol-rich curry made with mixed spices and vegetables benefits glucose homeostasis in Chinese males (Polyspice Study): a dose–response randomized controlled crossover trial
  55. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
  56. Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids
  57. The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat
  58. In Silico and in Vitro Interactions between Short Chain Fatty Acids and Human Histone Deacetylases
  59. Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy
  60. A novel LCMSMS method for quantitative measurement of short-chain fatty acids in human stool derivatized with 12 C- and 13 C-labelled aniline
  61. Common deregulated gene expression profiles and morphological changes in developing zebrafish larvae exposed to environmental-relevant high to low concentrations of glucocorticoids
  62. Application of Static Modeling ­­in the Prediction of In Vivo Drug–Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies
  63. Proteo-metabolomics in elucidating mechanisms of acetaminophen toxicity
  64. Targeted LC/MS-based quantitative profiling of 15 gut microbiome-derived short chain fatty acids in infant and adult stool
  65. Dronedarone inhibits CYP2J3 activity in H9c2 cardiomyocytes without mitochondrial toxicity
  66. Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells
  67. Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model
  68. In VitroActivity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B
  69. Phase I Metabolic Stability and Electrophilic Reactivity of 2-Phenylaminophenylacetic Acid Derived Compounds
  70. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites
  71. Metabolomic Characterizations of Liver Injury Caused by Acute Arsenic Toxicity in Zebrafish
  72. Metabolic Markers for Diabetic Retinopathy
  73. The Isotope-Coded Affinity Tag Method for Quantitative Protein Profile Comparison and Relative Quantitation of Cysteine Redox Modifications
  74. Metabonomic diagnosis of bladder cancer: what are the advantages and considerations?
  75. Gastrointestinal Symptoms and Altered Intestinal Permeability Induced by Combat Training Are Associated with Distinct Metabotypic Changes
  76. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone
  77. Understanding the cholesterol metabolism-perturbing effects of docosahexaenoic acid by gas chromatography–mass spectrometry targeted metabonomic profiling
  78. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A
  79. Global Metabonomic and Proteomic Analysis of Human Conjunctival Epithelial Cells (IOBA-NHC) in Response to Hyperosmotic Stress
  80. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer
  81. Investigation of Host–Gut Microbiota Modulation of Therapeutic Outcome
  82. In VitroPharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae
  83. Metabolic Profiling of CHO-AβPP695 Cells Revealed Mitochondrial Dysfunction Prior to Amyloid-β Pathology and Potential Therapeutic Effects of Both PPARγ and PPARα Agonisms for Alzheimer's Disease
  84. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
  85. Metabonomic Profiling of Bladder Cancer
  86. Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians
  87. Metabotyping of Docosahexaenoic Acid - Treated Alzheimer’s Disease Cell Model
  88. Development of an UPLC–MS/MS method for assaying the enzymatic activity of propionyl coenzyme-A carboxylase
  89. Non-invasive fecal metabonomic detection of colorectal cancer
  90. Applications of monolithic materials for sample preparation
  91. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model
  92. Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces
  93. Urinary Metabotyping of Bladder Cancer Using Two-Dimensional Gas Chromatography Time-of-Flight Mass Spectrometry
  94. Metabolically Functional Hepatocyte-Like Cells from Human Umbilical Cord Lining Epithelial Cells
  95. An automated Pearson's correlation change classification (APC3) approach for GC/MS metabonomic data using total ion chromatograms (TICs)
  96. Gas Chromatography/Mass Spectrometry-Based Metabonomics
  97. Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy
  98. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties
  99. Optimizing hollow-fiber-based pharmacokinetic assay via chemical stability study to account for inaccurate simulated drug clearance of rifampicin
  100. Metabonomic Profiling of TASTPM Transgenic Alzheimer’s Disease Mouse Model
  101. An Investigation of the Bioactivation Potential and Metabolism Profile of Zebrafish versus Human
  102. LC-MS-based metabolic characterization of high monoclonal antibody-producing Chinese hamster ovary cells
  103. Thomas O. Metz (Ed.): Metabolic profiling. Methods and protocols
  104. Interaction of Lapatinib with Cytochrome P450 3A5
  105. ChemInform Abstract: Trend Analysis of Metabonomics and Systematic Review of Metabonomics-derived Cancer Marker Metabolites
  106. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry
  107. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
  108. Metabonomics
  109. Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation
  110. Global urinary metabolic profiling procedures using gas chromatography–mass spectrometry
  111. Efficiency of a miniaturized silica monolithic cartridge in reducing matrix ions as demonstrated in the simultaneous extraction of morphine and codeine from urine samples for quantification with liquid chromatography-tandem mass spectrometry (LC-MS/MS)
  112. Characterization of The Human Tear Metabolome by LC–MS/MS
  113. Use of Urine Volatile Organic Compounds To Discriminate Tuberculosis Patients from Healthy Subjects
  114. Metabolic Profiling of 3-Nitropropionic Acid Early-Stage Huntington’s Disease Rat Model Using Gas Chromatography Time-of-Flight Mass Spectrometry
  115. Extraction of ketamine from urine using a miniature silica monolithic cartridge followed by quantification with liquid chromatography tandem mass spectrometry (LC-MS/MS)
  116. Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib
  117. Zebrafish for drug toxicity screening: bridging thein vitrocell-based models andin vivomammalian models
  118. Ultra-pressure liquid chromatography/tandem mass spectrometry targeted profiling of arachidonic acid and eicosanoids in human colorectal cancer
  119. Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells
  120. Comparative evaluation of software for retention time alignment of gas chromatography/time-of-flight mass spectrometry-based metabonomic data
  121. Trend analysis of metabonomics and systematic review of metabonomics-derived cancer marker metabolites
  122. Metabolic footprinting of tumorigenic and nontumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry
  123. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
  124. On-line chromatographic screening of matrix metalloproteinase inhibitors using immobilized MMP-9 enzyme reactor
  125. Application of silica-based monolith as solid phase extraction cartridge for extracting polar compounds from urine
  126. Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes
  127. Ultra-high performance liquid chromatography/time-of-flight mass spectrometry (UHPLC/TOFMS) for time-dependent profiling of raw and steamed Panax notoginseng
  128. Noninvasive Urinary Metabonomic Diagnosis of Human Bladder Cancer
  129. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity
  130. A sensitive LC/MS/MS bioanalysis assay of orally administered lipoic acid in rat blood and brain tissue
  131. Fluorescence-Based Liver Microsomal Assay for Screening of Pharmaceutical Reactive Metabolites Using a Glutathione Conjugated 96-Well Plate
  132. Metabolic Profiling of Rat Brain and Cognitive Behavioral Tasks: Potential Complementary Strategies in Preclinical Cognition Enhancement Research
  133. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity
  134. Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue
  135. Pharmaceutical metabolite profiling using quadrupole/ion mobility spectrometry/time-of-flight mass spectrometry
  136. Distribution study of orally administered lipoic acid in rat brain tissues
  137. Metabolic Profiling of Human Colorectal Cancer Using High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance (HR-MAS NMR) Spectroscopy and Gas Chromatography Mass Spectrometry (GC/MS)
  138. Development and validation of a gas chromatography/mass spectrometry metabonomic platform for the global profiling of urinary metabolites
  139. Metabonomics investigation of human urine after ingestion of green tea with gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry and1H NMR spectroscopy
  140. Oxidative Bioactivation and Toxicity of Leflunomide in Immortalized Human Hepatocytes and Kinetics of the Non-Enzymatic to Its Major etabolitie, A77 1726
  141. Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine
  142. Gas chromatography/mass spectrometry in metabolic profiling of biological fluids
  143. Investigation of the Drug–Drug Interaction Between α-Lipoic Acid and Valproate via Mitochondrial β-oxidation
  144. Bonding interfaces in wafer-level metal/adhesive bonded 3D integration
  145. Evaluation of BEH C18, BEH HILIC, and HSS T3 (C18) Column Chemistries for the UPLC-MS-MS Analysis of Glutathione, Glutathione Disulfide, and Ophthalmic Acid in Mouse Liver and Human Plasma
  146. Enhancing pharmaceutical analysis laboratory classes via the measurement of minerals in Berocca® effervescent tablets
  147. In Vitro Metabolism of Leflunomide by Mouse and Human Liver Microsomes
  148. Pharmacokinetic study of intraperitoneally administered troglitazone in mice using ultra-performance liquid chromatography/tandem mass spectrometry
  149. Ultra-performance liquid chromatography/time-of-flight mass spectrometry based metabolomics of raw and steamedPanax notoginseng
  150. Detection of aristolochic acid I, tetrandrine and fangchinoline in medicinal plants by high performance liquid chromatography and liquid chromatography/mass spectrometry
  151. Modeling Caco-2 permeability of drugs using immobilized artificial membrane chromatography and physicochemical descriptors
  152. Hydrophilic interaction liquid chromatography with tandem mass spectrometry for the determination of underivatized dencichine (β-N-oxalyl-L-α,β-diaminopropionic acid) inPanax medicinal plant species
  153. Application of Visual Basic in High-Throughput Mass Spectrometry-Directed Purification of Combinatorial Libraries
  154. Preparation and characterization of immunogens for antibody production against metanephrine and normetanephrine
  155. An automated LC method for the small-scale purification of organic molecules derived from combinatorial libraries
  156. Evaluation of degradation of urinary catecholamines and metanephrines and deconjugation of their sulfoconjugates using stability-indicating reversed-phase ion-pair HPLC with electrochemical detection
  157. High-performance liquid chromatographic assay for catecholamines and metanephrines using fluorimetric detection with pre-column 9-fluorenylmethyloxycarbonyl chloride derivatization
  158. High-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometric method for the analysis of catecholamines and metanephrines in human urine
  159. The value of analytical assays that are stability-indicating
  160. Enantiomeric separation of tramadol hydrochloride and its metabolites by cyclodextrin-mediated capillary zone electrophoresis